Related Experiment Video
Updated: Dec 27, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Molecular Components of the RCC Grade
1Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is a major cancer yet has long evaded extensive efforts to target it chemotherapeutically. Recent efforts to characterize its proteome and metabolome in a grade-defined manner has resulted in a global proteometabolomic reprogramming model yielding a number of potential drug targets, many of which are under the control of transcription factor and MYC proto-oncogene, bHLH transcription factor. Furthermore, through the use of conventional technologies such as immunohistochemistry, protein moonlighting, a phenomenon wherein a single protein performs more than one distinct biochemical or biophysical functions, is emerging as a second mode of operation for ccRCC metabolo-proteomic reprogramming. This renders the subcellular localization of the grade-defining biomarkers an additional layer of grade-defining ccRCC molecular signature, although its functional significance in ccRCC etiology is only beginning to emerge.
Insights
Clear cell renal cell carcinoma (ccRCC) shows proteometabolomic reprogramming. Protein moonlighting and biomarker localization offer new therapeutic targets for this challenging kidney cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Clear cell renal cell carcinoma (ccRCC) remains difficult to treat with chemotherapy.
- Recent proteomic and metabolomic studies reveal a grade-defined reprogramming model in ccRCC.
- This model identifies potential therapeutic targets, many regulated by the MYC transcription factor.
Purpose of the Study:
- To explore novel therapeutic strategies for ccRCC.
- To investigate the role of protein moonlighting in ccRCC.
- To understand the significance of subcellular localization of biomarkers in ccRCC progression.
Main Methods:
- Proteomic and metabolomic analyses in a grade-defined manner.
- Characterization of transcription factor control, including MYC.
- Application of immunohistochemistry to study protein moonlighting and biomarker localization.
Main Results:
- A global proteometabolomic reprogramming model for ccRCC was established.
- MYC proto-oncogene, bHLH transcription factor, was identified as a key regulator.
- Protein moonlighting was recognized as a factor in ccRCC metabolic reprogramming.
- Subcellular localization of biomarkers emerged as a critical molecular signature.
Conclusions:
- The proteometabolomic reprogramming model provides new drug targets for ccRCC.
- Protein moonlighting and biomarker subcellular localization represent novel aspects of ccRCC pathology.
- Further research into the functional significance of these findings is warranted for ccRCC treatment.
More Related Videos
Related Concept Videos
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Classification of Elements and Compounds
Compounds are pure substances composed of two or more elements in fixed, definite proportions. Compounds are classified as ionic or molecular (covalent) based on the bonds...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Aggregates Classification
Petrographic classification groups aggregates based on common mineralogical characteristics. Some of the common mineral groups found in aggregates are...
Aggregate Cement Ratio
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...

